DS-6930 is a novel agonist of PPARγ, with an EC50 of 41 nM. DS-6930 has the potential to significantly lower plasma glucose (PG) while having fewer negative effects related to PPARγ than Rosiglitazone. DS-6930 can be applied to diabetes research.

Physicochemical Properties

Molecular Formula	C23H21N3O4
Exact Mass	403.153
CAS #	1242328-82-0
Related CAS #	1242328-82-0
PubChem CID	46908905
Appearance	Typically exists as solid at room temperature
LogP	4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	6
Heavy Atom Count	30
Complexity	591
Defined Atom Stereocenter Count	0
InChi Key	GEGLFSVXCSGSOB-UHFFFAOYSA-N
InChi Code	InChI=1S/C23H21N3O4/c1-14-9-15(2)22(24-12-14)30-18-7-8-19-20(11-18)26(3)21(25-19)13-29-17-6-4-5-16(10-17)23(27)28/h4-12H,13H2,1-3H3,(H,27,28)
Chemical Name	3-[[6-(3,5-dimethylpyridin-2-yl)oxy-1-methylbenzimidazol-2-yl]methoxy]benzoic acid
Synonyms	DS-6930
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	PPARγ (EC50 = 41 nM)
ln Vitro	DS-6930 exhibits strong PPARα or PPARδ selectivity (13% PPARα activation at 10 µM and no PPARδ activation at 10 µM), and shows high potency with an intermediate PPARγ agonist activity (EC50=41 nM, Emax=68%) in vitro [1]. DS-6930 (10-100 µM) shows reduced toxicity to cells at 100 µM[1].
ln Vivo	DS-6930 (0.1-3 mg/kg; p.o. for 3 weeks) dhas a dose-dependent effect on rats' plasma glucose (PG) levels[1]. DS-6930 (100-1000 mg/kg; p.o.for 4 weeks) has no notable effect on the relative heart weight of F344 rats and has no effect on any liver enzyme activities[1]. DS-6930 shows Tmax=1.8 h, AUC0-24h=0.861 h•µg/mL, and Cmax=0.0792 µg/mL after oral (0.3 mg/kg) administration in rats on day 22[1]. DS-6930 shows that when given orally (3 mg/kg) in cynomolgus monkeys, Cmax=2.25 µg/mL, Tmax=5.0 h, T1/2=13.5 h, and AUClast=23.5 h•µg/mL[1]. DS-6930 shows remarkable distribution volume at steady state (Vss=0.36 L/kg), total body clearance (CL=2.06 mL/min/kg), and bioavailability (F=89%) after intravenous (1 mg/kg) administration in cynomolgus monkeys[1].
Animal Protocol	Male ZDF rats[1] 0.1, 0.3, 1, 3 mg/kg P.o. daily for 3 weeks
References	[1]. Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization. Bioorg Med Chem. 2018 Oct 1;26(18):5099-5117.

Solubility Data

Solubility (In Vitro)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)